A case report of a lung cancer patient with two uncommon EGFR mutations and a review of the literature: two sides of the same coin.
Journal
Anti-cancer drugs
ISSN: 1473-5741
Titre abrégé: Anticancer Drugs
Pays: England
ID NLM: 9100823
Informations de publication
Date de publication:
10 Mar 2023
10 Mar 2023
Historique:
entrez:
17
4
2023
pubmed:
18
4
2023
medline:
18
4
2023
Statut:
aheadofprint
Résumé
Lung cancer is the malignancy with the highest morbidity and mortality worldwide. Approximately 60% of non-small cell lung cancer (NSCLC) presents driver alterations most of which are targetable. Nowadays, limited clinical data are available regarding the efficacy of epithelial growth factor receptor (EGFR) tyrosine kinase inhibitors in patients with NSCLC harboring uncommon EGFR mutations, considering their heterogeneity. Herein, we report a rare case of EGFR-mutated lung adenocarcinoma which has developed into squamous cell carcinoma with uncommon EGFR (Ex18) compound mutations and phosphatidylinositol 3-kinase mutation receiving afatinib at the forefront.
Identifiants
pubmed: 37067984
doi: 10.1097/CAD.0000000000001517
pii: 00001813-990000000-00184
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019; 30:863–870.
Chevallier M, Borgeaud M, Addeo A, Friedlaender A. Oncogenic driver mutations in non-small cell lung cancer: past, present and future. World J Clin Oncol 2021; 12:217–237.
Hanna NH, Robinson AG, Temin S, Baker S Jr, Brahmer JR, Ellis PM, et al. Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update. J Clin Oncol 2021; 39:1040–1091.
Metro G, Crinò L. Advances on EGFR mutation for lung cancer. Transl Lung Cancer Res 2012; 1:5–13.
Puliafito I, Esposito F, Raciti G, Giuffrida P, Caltavuturo C, Colarossi C, et al. Metabolic complete tumor response in a patient with epidermal growth factor receptor mutant non-small cell lung cancer treated with a reduced dose of afatinib. J Int Med Res 2022; 50:3000605211058864.
Van Acker L, Stevens D, Vermaelen K, Surmont V. Afatinib for the treatment of advanced non-small-cell lung cancer harboring an epidermal growth factor receptor exon 18 E709_T710delinsD mutation: a case report. J Med Case Rep 2021; 15:562.
Wu YL, Zhou C, Hu C-P, Feng JF, Lu S, Huang Y, et al. LUX-Lung 6: a randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung. J Clin Oncol 2013; 31:8016–8016.
Yang JC-H, Schuler MH, Yamamoto N, O’Byrne KJ, Hirsh V, Mok T, et al. LUX-Lung 3: a randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J Clin Oncol 2012; 30:LBA7500.
Yang JC-H, Wu Y-L, Schuler M, Sebastian M, Popat S, Yamamoto N, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015; 16:141–151.
Kobayashi Y, Togashi Y, Yatabe Y, Mizuuchi H, Jangchul P, Kondo C, et al. EGFR exon 18 mutations in lung cancer: molecular predictors of augmented sensitivity to afatinib or neratinib as compared with first- or third-generation TKIs. Clin Cancer Res 2015; 21:5305–5313.
Yang JC-H, Schuler M, Popat S, Miura S, Park K, Passaro A, et al. Afatinib for the treatment of non-small cell lung cancer harboring uncommon EGFR mutations: an updated database of 1023 cases brief report. Front Oncol 2022; 12:834704.
Popat S, Hsia T-C, Hung J-Y, Jung HA, Shih J-Y, Park CK, et al. Tyrosine kinase inhibitor activity in patients with NSCLC harboring uncommon EGFR mutations: a Retrospective International Cohort Study (UpSwinG). Oncologist 2022; 27:255–265.
Kim M-H, Choi CM, Lee SY, Park CK, Chang YS, Lee KY, et al. First-line afatinib in patients with non-small-cell lung cancer with uncommon EGFR mutations in South Korea. Anticancer Res 2022; 42:1615–1622.
Passaro A, Mok T, Peters S, Popat S, Ahn M-J, de Marinis F. Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions, EGFR mutations. J Thorac Oncol 2021; 16:764–773.
Vu TH, Nguyen HTT, Dao LK, Duong CK, Nguyen CV, Doan TT, et al. Effectiveness and tolerability of first-line afatinib for advanced EGFR-mutant non-small cell lung cancer in Vietnam. Asian Pac J Cancer Prev 2021; 22:1581–1590.
Tan J, Hu C, Deng P, Wan R, Cao L, Li M, et al. The predictive values of advanced non-small cell lung cancer patients harboring uncommon EGFR mutations – the mutation patterns, use of different generations of EGFR-TKIs, and concurrent genetic alterations. Front Oncol 2021; 11:646577.
Wu S-G, Yu C-J, Yang JC-H, Shih J-Y. The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation. Ther Adv Med Oncol 2020; 12:1758835920946156.
Kanazu M, Mori M, Kimura M, Nishino K, Shiroyama T, Nagatomo I, et al. Effectiveness of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with uncommon EGFR mutations: a multicenter observational study. Thorac Cancer 2021; 12:90–96.
Moran T, Taus A, Arriola E, Aguado C, Dómine M, Rueda AG, et al. Clinical activity of afatinib in patients with non–small-cell lung cancer harboring uncommon EGFR mutations: a Spanish retrospective multicenter study. Clin Lung Cancer 2020; 21:428–436.e2.
Ohara G, Okauchi S, Sasatani Y, Shiozawa T, Yamada H, Miyazaki K, et al. Long-term survival with afatinib in a patient with lung adenocarcinoma harboring double uncommon EGFR L861Q and G719X mutations. In Vivo 2020; 34:1459–1462.
Long X, Qin T, Lin J. Great efficacy of afatinib in a patient with lung adenocarcinoma harboring EGFR L833V/H835L mutations: a case report. OncoTargets Ther 2020; 13:10689–10692.
Ho G-F, Chai C-S, Alip A, Wahid MIA, Abdullah MM, Foo Y-C, et al. Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study. BMC Cancer 2019; 19:896.
Heigener DF, Schumann C, Sebastian M, Sadjadian P, Stehle I, Märten A, et al.; Afatinib Compassionate Use Consortium (ACUC). Afatinib in non-small cell lung cancer harboring uncommon EGFR mutations pretreated with reversible EGFR inhibitors. Oncologist 2015; 20:1167–1174.
Levin PA, Mayer M, Hoskin S, Sailors J, Oliver DH, Gerber DE. Histologic transformation from adenocarcinoma to squamous cell carcinoma as a mechanism of resistance to EGFR inhibition. J Thorac Oncol 2015; 10:e86–e88.
Kapoor A, Noronha V, Shetty OA, Kashyap L, Kumar A, Chandrani P, et al. Concurrent EGFR and PIK3CA mutations in non-small-cell lung cancer. Cancer Res Stat Treat 2021; 4:541–546.